Meta-analysis of depressive symptoms in dual-diagnosis schizophrenia

References

• Kavanagh DJ, McGrath J, Saunders JB, Dore G, Clark D. Substance misuse in patients with schizophrenia: epidemiology and management. Drugs 2002; 62: 743–755
   PubMed Web of Science ®Google Scholar
• Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990; 264: 2511–2518
   PubMed Web of Science ®Google Scholar
• Negrete JC. Clinical aspects of substance abuse in persons with schizophrenia. Can J Psychiatry 2003; 48: 14–21
   PubMed Web of Science ®Google Scholar
• Mueser KT, Drake RE, Wallach MA. Dual diagnosis: a review of etiological theories. Addict Behav 1998; 23: 717–734
   PubMed Web of Science ®Google Scholar
• Brady KT, Killeen T, Jarrell P. Depression in alcoholic schizophrenic patients. Am J Psychiatry 1993; 150: 1255–1256
   PubMed Web of Science ®Google Scholar
• Cooper L, Liberman D, Tucker D, Nuechterlein KH, Tsuang J, Barnett HL. Neurocognitive deficits in the dually diagnosed with schizophrenia and cocaine abuse. Psychiatr Rehab Skills 1999; 3: 231–245
   Google Scholar
• Krausz M, Mass R, Haasen C, Gross J. Psychopathology in patients with schizophrenia and substance abuse: a comparative clinical study. Psychopathology 1996; 29: 95–103
   PubMed Web of Science ®Google Scholar
• Scheller-Gilkey G, Thomas SM, Woolwine BJ, Miller AH. Increased early life stress and depressive symptoms in patients with comorbid substance abuse and schizophrenia. Schizophr Bull 2002; 28: 223–231
   PubMed Web of Science ®Google Scholar
• Borg L, Kreek MJ. The pharmacology of opioids. Principles of addiction medicine, AW Graham. The American Society of Addiction Medicine, Chevy Chase, MD 2003; 141–153
   Google Scholar
• Bossavo GB. Cannabis abuse as a risk factor for depressive symptoms. Am J Psychiatry 1002; 158:2033–2037.
   PubMed Web of Science ®Google Scholar
• Dackis CA, O'Brien CP. Cocaine dependence: a disease of the brain's reward centers. J Subst Abuse Treat 2001; 21: 111–117
   PubMed Web of Science ®Google Scholar
• Heinz A, Mann K, Weinberger DR, Goldman D. Serotonergic dysfunction, negative mood states, and response to alcohol. Alcohol Clin Exp Res 2001; 25: 487–495
   PubMed Web of Science ®Google Scholar
• Barnes TR, Mutsatsa SH, Hutton SB, Watt HC, Joyce EM. Comorbid substance use and age at onset of schizophrenia. Br J Psychiatry 2006; 188: 237–242
   PubMed Web of Science ®Google Scholar
• Sevy S, Robinson DG, Holloway S, et al. Correlates of substance misuse in patients with first-episode schizophrenia and schizoaffective disorder. Acta Psychiatr Scand 2001; 104: 367–374
   PubMed Web of Science ®Google Scholar
• Herz MI, Marder SR. Schizophrenia: comprehensive treatment and management. Lippincott, Williams & Wilkins, Philadelphia, PA 2002
   Google Scholar
• Siris SG, Bench C. Depression and schizophrenia. Schizophrenia2nd edn, SR Hirsch, DR Weinberger. Blackwell Publishing, Malden, MA 2003
   Google Scholar
• Hawton K, Sutton L, Haw C, Sinclair J, Deeks JJ. Schizophrenia and suicide: systematic review of risk factors. Br J Psychiatry 2005; 187: 9–20
   PubMed Web of Science ®Google Scholar
• Montross LP, Zisook S, Kasckow J. Suicide among patients with schizophrenia: a consideration of risk and protective factors. Ann Clin Psychiatry 2005; 17: 173–182
   PubMedGoogle Scholar
• Caldwell CB, Gottesman Ii. Schizophrenia: a high-risk factor for suicide: clues to risk reduction. Suicide Life Threat Behav 1992; 22: 479–493
   PubMed Web of Science ®Google Scholar
• Siris SG. Depressive symptoms in the course of schizophrenia. Depression in schizophrenia, LE Delisi. American Psychiatric Press, Washington, DC 1990
   Google Scholar
• Potvin S, Sepehry AA, Stip E. A meta-analysis of negative symptoms in dual diagnosis schizophrenia. Psychol Med 2006; 36: 431–440
   PubMed Web of Science ®Google Scholar
• Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56–62
   PubMed Web of Science ®Google Scholar
• Addington D, Addington J, Maticka-Tyndale E, Joyce J. Reliability and validity of a depression rating scale for schizophrenics. Schizophr Res 1992; 6: 201–208
   PubMed Web of Science ®Google Scholar
• Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561–571
   PubMed Web of Science ®Google Scholar
• Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261–276
   PubMed Web of Science ®Google Scholar
• Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962; 10: 799–812
   Web of Science ®Google Scholar
• Borenstein M, Rothstein H. Comprehensive Meta-Analysis: a computer program for research synthesis2nd edn. Biostat, Englewood, New Jersey 2005
   Google Scholar
• Cooper H, Hedges L. Potentials and limitations of research synthesis. The handbook of research synthesis, H Cooper, LV Hedges. Russell Sage Foundation Publications, 1964, New York 1994; 301–323
   Google Scholar
• Dersimonian R, Laird N. 1986. Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177–188.
   PubMed Web of Science ®Google Scholar
• Coldham EL, Addington J, Addington D. Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand 2002; 106: 286–290
   PubMed Web of Science ®Google Scholar
• Green AI, Tohen MF, Hamer RM, et al. First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophr Res 2004; 66: 125–135
   PubMed Web of Science ®Google Scholar
• Swofford CD, Kasckow JW, Scheller-Gilkey G, Inderbitzin LB. Substance use: a powerful predictor of relapse in schizophrenia. Schizophr Res 1996; 20: 145–151
   PubMed Web of Science ®Google Scholar
• Baker A, Bucci S, Lewin TJ, Richmond R, Carr VJ. Comparisons between psychosis samples with different patterns of substance use recruited for clinical and epidemiological studies. Psychiatry Res 2005; 134: 241–250
   PubMed Web of Science ®Google Scholar
• Scheller-Gilkey G, Moynes K, Cooper I, Kant C, Miller AH. Early life stress and PTSD symptoms in patients with comorbid schizophrenia and substance abuse. Schizophr Res 2004; 69: 167–174
   PubMed Web of Science ®Google Scholar
• Scheller-Gilkey G, Woolwine BJ, Cooper I, Gay O, Moynes KA, Miller AH. Relationship of clinical symptoms and substance use in schizophrenia patients on conventional versus atypical antipsychotics. Am J Drug Alcohol Abuse 2003; 29: 553–566
   PubMed Web of Science ®Google Scholar
• Margolese HC, Carlos Negrete J, Tempier R, Gill K. A 12-month prospective follow-up study of patients with schizophrenia-spectrum disorders and substance abuse: changes in psychiatric symptoms and substance use. Schizophr Res 2006; 83: 65–75
   PubMed Web of Science ®Google Scholar
• Margolese HC, Malchy L, Negrete JC, Tempier R, Gill K. Drug and alcohol use among patients with schizophrenia and related psychoses: levels and consequences. Schizophr Res 2004; 67: 157–166
   PubMed Web of Science ®Google Scholar
• Van Mastrigt S, Addington J, Addington D. Substance misuse at presentation to an early psychosis program. Soc Psychiatry Psychiatr Epidemiol 2004; 39: 69–72
   PubMed Web of Science ®Google Scholar
• Addington J, Addington D. Patterns, predictors and impact of substance use in early psychosis: a longitudinal study. Acta Psychiatr Scand 2007; 115: 304–309
   PubMed Web of Science ®Google Scholar
• Akvardar Y, Tumuklu M, Akdede BB, Ulas H, Kitis A, Alptekin K. Substance use among patients with schizophrenia in a university hospital. Bull Clin Psychopharmacol 2004; 14: 191–197
   Google Scholar
• DeQuardo JR, Carpenter CF, Tandon R. Patterns of substance abuse in schizophrenia: nature and significance. J Psychiatr Res 1994; 28: 267–275
   PubMed Web of Science ®Google Scholar
• Kamali M, Kelly L, Gervin M, Browne S, Larkin C, O'Callaghan E. (2000). The prevalence of comorbid substance misuse and its influence on suicidal ideation among in-patients with schizophrenia. Acta Psychiatr Scand 2000; 101:452–456.
   PubMed Web of Science ®Google Scholar
• Mancini-Marie A, Potvin S, Fahim C, Beauregard M, Mensour B, Stip E. Neural correlates of the affect regulation model in schizophrenia patients with substance use history: a functional magnetic resonance imaging study. J Clin Psychiatry 2006; 67: 342–350
   PubMed Web of Science ®Google Scholar
• Mohamed S, Bondi MW, Kasckow JW, Golshan S, Jeste DV. (2006). Neurocognitive functioning in dually diagnosed middle aged and elderly patients with alcoholism and schizophrenia. Int J Geriatr Psychiatry 2006; 21:711–718.
   PubMed Web of Science ®Google Scholar
• Monterrubio S, Solowij N, Meyer BJ, Turner N. Fatty acid relationships in former cannabis users with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 280–285
   PubMed Web of Science ®Google Scholar
• Rabinowitz J, Bromet EJ, Lavelle J, Carlson G, Kovasznay B, Schwartz JE. Prevalence and severity of substance use disorders and onset of psychosis in first-admission psychotic patients. Psychol Med 1998; 28: 1411–1419
   PubMed Web of Science ®Google Scholar
• Sevy S, Kay SR, Opler LA, van Praag HM. Significance of cocaine history in schizophrenia. J Nerv Ment Dis 1990; 178: 642–648
   PubMed Web of Science ®Google Scholar
• Swartz MS, Wagner HR, Swanson JW, et al. Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study. J Nerv Ment Dis 2006; 194: 164–172
   PubMed Web of Science ®Google Scholar
• Ries RK, Russo J, Wingerson D, et al. Shorter hospital stays and more rapid improvement among patients with schizophrenia and substance disorders. Psychiatr Serv 2000; 51: 210–215
   PubMed Web of Science ®Google Scholar
• Swofford CD, Scheller-Gilkey G, Miller AH, Woolwine B, Mance R. Double jeopardy: schizophrenia and substance use. Am J Drug Alcohol Abuse 2000; 26: 343–353
   PubMed Web of Science ®Google Scholar
• Blanchard JJ, Brown SA, Horan WP, Sherwood AR. Substance use disorders in schizophrenia: review, integration, and a proposed model. Clin Psychol Rev 2000; 20: 207–234
   PubMed Web of Science ®Google Scholar
• Potvin S, Stip E, Roy JY. Schizophrenia and addiction: an evaluation of the self-medication hypothesis]. Encephale 2003; 29: 193–203
   PubMed Web of Science ®Google Scholar
• Rosnow RL, Rosenthal R. Computing contrasts, effect sizes, and counternulls on other people's published data: general procedures for research consumers. Psychol Methods 1996; 1: 331–340
   Web of Science ®Google Scholar
• Cohen J. Statistical power analysis for the behavioral sciences. Lawrence Earlbaum Associates, Hillsdale, NJ 1988
   Google Scholar
• Muller MJ, Kienzle B, Dahmen N. Depression, emotional blunting, and akinesia in schizophrenia. Overlap and differentiation. Eur J Health Econ 2002; 3(Suppl 2)S99–103
   PubMedGoogle Scholar
• Reine G, Bernard D, Auquier P, Le Fur B, Lancon C. [Psychometric properties of French version of the Calgary depression scale for schizophrenics (CDSS)]. Encephale 2000; 26: 52–61
   PubMed Web of Science ®Google Scholar
• Khantzian EJ. The self-medication hypothesis of substance use disorders: a reconsideration and recent applications. Harv Rev Psychiatry 1997; 4: 231–244
   PubMed Web of Science ®Google Scholar